CA1215061A - 17-18-deshydro-apovincaminol et methode de preparation - Google Patents

17-18-deshydro-apovincaminol et methode de preparation

Info

Publication number: CA1215061A
Authority: CA; Canada
Prior art keywords: formula; compound; dehydro; acid addition; addition salt
Prior art date: 1981-02-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000480556A

Other languages

English (en)

Inventor

Maria Nee Balazs Zajer

Janos Galambos

Egon Karpati

Gyongyver Nee Soos Kiraly

Arpad Kiraly

Lilla Forgach

Tibor Keve

Laszlo Szporny

Csaba Lorincz

Bela Rosdy

Bela Zsadon

Gyorgy Fekete

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Richter Gedeon Vegyeszeti Gyar Nyrt

Original Assignee

Richter Gedeon Vegyeszeti Gyar RT

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-02-11

Filing date

1985-05-01

Publication date

1986-12-09

1981-02-11 Priority claimed from HU81321A external-priority patent/HU183323B/hu

1985-05-01 Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT

1985-05-01 Priority to CA000480556A priority Critical patent/CA1215061A/fr

1986-12-09 Application granted granted Critical

1986-12-09 Publication of CA1215061A publication Critical patent/CA1215061A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 15
150000001875 compounds Chemical class 0.000 claims abstract description 52
150000003839 salts Chemical class 0.000 claims abstract description 29
239000002253 acid Substances 0.000 claims abstract description 22
239000003638 chemical reducing agent Substances 0.000 claims abstract description 9
238000004519 manufacturing process Methods 0.000 claims abstract description 6
238000006243 chemical reaction Methods 0.000 claims description 9
-1 lithium-aluminium hydride Chemical group 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 5
229910052987 metal hydride Inorganic materials 0.000 claims description 4
150000004681 metal hydrides Chemical class 0.000 claims description 4
239000003960 organic solvent Substances 0.000 claims description 4
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
229950006936 apovincamine Drugs 0.000 claims description 2
239000012280 lithium aluminium hydride Substances 0.000 claims 2
229910052782 aluminium Inorganic materials 0.000 claims 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 abstract description 9
208000017520 skin disease Diseases 0.000 abstract description 6
238000002360 preparation method Methods 0.000 abstract description 5
VYHPNRMBGSEPHR-DGPALRBDSA-N ac1l5axb Chemical compound C([C@]([C@@H]12)(C=3)CC)CCN2CCC(C2=CC=CC=C22)=C1N2C=3COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 VYHPNRMBGSEPHR-DGPALRBDSA-N 0.000 abstract description 3
239000000543 intermediate Substances 0.000 abstract 1
239000004480 active ingredient Substances 0.000 description 22
239000000243 solution Substances 0.000 description 22
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
230000000694 effects Effects 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
239000000203 mixture Substances 0.000 description 13
239000006071 cream Substances 0.000 description 12
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 12
238000012360 testing method Methods 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
238000011282 treatment Methods 0.000 description 8
241000283690 Bos taurus Species 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
229930008281 A03AD01 - Papaverine Natural products 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
239000012024 dehydrating agents‎ Substances 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
229960001789 papaverine Drugs 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
239000012071 phase Substances 0.000 description 5
RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical class C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
230000010933 acylation Effects 0.000 description 4
238000005917 acylation reaction Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 4
239000002674 ointment Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
BQGJXFQCMYJENQ-GIVPXCGWSA-N 14,15-dehydrovincamine Chemical compound C12=CC=CC=C2N2[C@@](O)(C(=O)OC)C[C@@]3(CC)[C@H]4C2=C1CCN4CC=C3 BQGJXFQCMYJENQ-GIVPXCGWSA-N 0.000 description 3
BQGJXFQCMYJENQ-UHFFFAOYSA-N 14-epi-Delta17-vincamine Natural products C12=CC=CC=C2N2C(O)(C(=O)OC)CC3(CC)C4C2=C1CCN4CC=C3 BQGJXFQCMYJENQ-UHFFFAOYSA-N 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000005662 Paraffin oil Substances 0.000 description 3
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
206010040844 Skin exfoliation Diseases 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000006260 foam Substances 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
GIGFIWJRTMBSRP-ACRUOGEOSA-N (-)-vincadifformine Chemical compound C1C(C(=O)OC)=C2NC3=CC=CC=C3[C@@]22CCN3CCC[C@]1(CC)[C@@H]23 GIGFIWJRTMBSRP-ACRUOGEOSA-N 0.000 description 2
SJSOFNCYXJUNBT-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OC SJSOFNCYXJUNBT-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
240000007371 Cuscuta campestris Species 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
241000282320 Panthera leo Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
229940082500 cetostearyl alcohol Drugs 0.000 description 2
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000035618 desquamation Effects 0.000 description 2
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940125532 enzyme inhibitor Drugs 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
229960002726 vincamine Drugs 0.000 description 2
RLLPVAHGXHCWKJ-IEBWSBKVSA-N (3-phenoxyphenyl)methyl (1s,3s)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(Cl)Cl)[C@@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-IEBWSBKVSA-N 0.000 description 1
IWPZKOJSYQZABD-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Natural products COC1=CC(OC)=CC(C(O)=O)=C1 IWPZKOJSYQZABD-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
241001661930 Aspidosperma Species 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
235000016795 Cola Nutrition 0.000 description 1
241001634499 Cola Species 0.000 description 1
235000011824 Cola pachycarpa Nutrition 0.000 description 1
GIGFIWJRTMBSRP-UHFFFAOYSA-N DL-Vincadifformin Natural products C1C(C(=O)OC)=C2NC3=CC=CC=C3C22CCN3CCCC1(CC)C23 GIGFIWJRTMBSRP-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241001444201 Falco tinnunculus Species 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000700605 Viruses Species 0.000 description 1
BQGJXFQCMYJENQ-HLAWJBBLSA-N ac1l4aa8 Chemical compound C12=CC=CC=C2N2[C@](O)(C(=O)OC)C[C@@]3(CC)[C@H]4C2=C1CCN4CC=C3 BQGJXFQCMYJENQ-HLAWJBBLSA-N 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002682 anti-psoriatic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
229960001270 d- tartaric acid Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229940042902 flumethasone pivalate Drugs 0.000 description 1
JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
230000006028 immune-suppresssive effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000011269 tar Substances 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
NAMSIRMSFVGAKD-UHFFFAOYSA-N vincadifformine Natural products CCC12CCCN3CCC4(C13)C(Nc1cc(OC)ccc41)=C(C2)C(=O)OC NAMSIRMSFVGAKD-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000480556A 1981-02-11 1985-05-01 17-18-deshydro-apovincaminol et methode de preparation Expired CA1215061A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000480556A CA1215061A (fr)	1981-02-11	1985-05-01	17-18-deshydro-apovincaminol et methode de preparation

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
HU321/81		1981-02-11
HU81321A HU183323B (en)	1981-02-11	1981-02-11	Process for producing 17,18-dihydro-apovincaminol-3-comma down comma aaove-4-comma down comma above-5-comma down comma aaove-trimethoxy-benzoate and acid additional salts thereof
CA000395934A CA1202029A (fr)	1981-02-11	1982-02-10	17,18-deshydro-apovincaminol-3',4',5'- trimethoxybenzoate, intermediaire, et procede de preparation
CA000480556A CA1215061A (fr)	1981-02-11	1985-05-01	17-18-deshydro-apovincaminol et methode de preparation

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000395934A Division CA1202029A (fr)	1981-02-11	1982-02-10	17,18-deshydro-apovincaminol-3',4',5'- trimethoxybenzoate, intermediaire, et procede de preparation

Publications (1)

Publication Number	Publication Date
CA1215061A true CA1215061A (fr)	1986-12-09

Family

ID=25669566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000480556A Expired CA1215061A (fr)	1981-02-11	1985-05-01	17-18-deshydro-apovincaminol et methode de preparation

Country Status (1)

Country	Link
CA (1)	CA1215061A (fr)

1985
- 1985-05-01 CA CA000480556A patent/CA1215061A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2003-12-09	MKEX	Expiry

Publication	Publication Date	Title
FR2466465A1 (fr)	1981-04-10	Derives de d-6-n-propylergolines, leur procede de preparation et compositions pharmaceutiques en contenant
EP0231709B1 (fr)	1992-07-22	Nouvelles phényl-naphtyridines fonctionnalisées en position-3, leur procédé de préparation, médicaments les contenant, notamment anti-ulcères
FR2540109A1 (fr)	1984-08-03	Imino-2 pyrrolidines, leur procede de preparation et leurs applications en therapeutique
US4424223A (en)	1984-01-03	Polycyclic compounds containing a double bond in the D-ring pharmaceutical compositions containing them, and methods of treating psoriasis with them
MC1693A1 (fr)	1986-07-18	Nouveaux composes,compositions les contenant et intermediaires pour leur preparation
CA1265520A (fr)	1990-02-06	Derives d'apovincaminol, procede de preparation et composes pharmaceutiques les contenant
EP0306356B1 (fr)	1993-05-19	Dérivés condensés de la pipéridine, leur procédé de préparation et les intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
US4196206A (en)	1980-04-01	Pyridyl-piperazine derivative with anti-arrythmic effect
FR2499573A1 (fr)	1982-08-13	Composes polycycliques substitues sur le noyau a, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0034521B1 (fr)	1983-03-23	Médicament analgésique contenant de la 1-(3'benzofuryl)-4-benzylpipérazine et son procédé de préparation
EP0395526A1 (fr)	1990-10-31	Nouveaux dérivés benzothiazolinoniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US4424224A (en)	1984-01-03	Apovincaminol derivative and compositions and methods utilizing it for treating psoriasis
BE874322R (fr)	1979-08-21	Nouveaux composes heterocycliques, leur preparation et leur application comme medicaments
GB2094787A (en)	1982-09-22	New apovincaminol derivatives
Murray et al.	1953	3, 4-DIHYDROXYPHENYLACETIC ACID—A METABOLITE OF QUERCETIN
BE838902A (fr)	1976-08-24	Nouveaux derives du benzo-cyclophepta-thiophene, leur preparation et leur application comme medicaments
BE839469A (fr)	1976-09-13	Nouvelles 5,6-diaryl-1,2,4-triazines et leur utilisation comme agents anti-inflammatoires locaux
CH650507A5 (en)	1985-07-31	Apovincaminol derivatives, a process for their preparation and drugs containing these compounds